Participating in the Rheumatoid Arthritis DRIVE Study is a way for patients with rheumatoid arthritis (RA) to contribute to treatment decisions, help guide therapy selections, and improve patient outcomes. 

Rheumatoid arthritis is the most common form of autoimmune arthritis. In fact, 1.3 million Americans are affected by this condition. It occurs when the immune system attacks healthy tissue. The tissue targeted will be hit with inflammation, and in the instance of RA, the joints are commonly affected. 

RA primarily affects smaller joints in the hands and feet. However, it is capable of affecting organs. Women between the ages of 30 and 50 are the primary demographic with this condition. Rheumatoid arthritis was commonly recognized as a disabling illness, but recent treatments have made living with RA easier.

Rheumatoid arthritis is complex and affects different people in different ways. Some medications work for some people, but not others. Fortunately, there are research studies looking at individual disease biology to improve disease outcomes. This study opportunity will help match a patient with a treatment that closely matches his or her individual disease biology with a single blood draw.